Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860259 | 0.87 | KMT2A (0.57) | KMT2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL1317767 | 0.84 | MAOB (0.56) | KMT2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL2559289 | 0.79 | SMN1; SMN2 (0.79) | KMT2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL7267474 | 0.79 | SMN1; SMN2 (0.79) | KMT2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL29853676 | 0.79 | SMN1; SMN2 (0.79) | KMT2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL881297 | 0.79 | LMNA (0.59) | KMT2ASMN1; SMN2NPC1MEN1POLB | |
| SCHEMBL6239769 | 0.79 | KMT2A (0.60) | KMT2ASMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL14389071 | 0.79 | SMN1; SMN2 (0.52) | KMT2AAKR1C3AKR1C2SMN1; SMN2KDM4E | |
| SCHEMBL2087813 | 0.78 | AKR1C3 (0.64) | KMT2AAKR1C3AKR1C2KDM4EMEN1 | |
| SCHEMBL29956237 | 0.78 | AKR1C3 (0.64) | KMT2AAKR1C3AKR1C2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-8475776-B2 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8475776-B2 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1373260-A1 | DIBENZO C]CHROMEN-6-ONE DERIVATIVES AS ANTI-CANCER AGENTS | Nanodesign Inc. (CA) | 2004-01-02 | — | — | EP | disclosed |
| US-6632835-B2 | Antiproliferative effects against epithelial cancer cell lines and endothelial cells | NANODESIGN INC. (CA) | 2003-10-14 | — | — | US | disclosed |
| US-6599921-B2 | Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives | NANODESIGN, INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20020156077-A1 | Non-steroidal estrogen receptor ligands | PALOMA PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002066428-A2 | NON-STEROIDAL ESTROGEN RECEPTOR LIGANDS | NANODESIGN INC. (CA) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066467-A1 | DIBENZO[C]CHROMEN-6-ONE DERIVATIVES AS ANTI-CANCER AGENTS | NANODESIGN INC. (CA) | 2002-08-29 | — | — | WO | disclosed |
| US-20020115711-A1 | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents | PALOMA PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156077-A1 | Non-steroidal estrogen receptor ligands | ESRRA, ESRRB, ESRRG | KMT2A 4447/4885AKR1C3 417/4885AKR1C2 487/4885 |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | KMT2A 2995/4885AKR1C3 814/4885AKR1C2 614/4885 |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, FLT1 | KMT2A 4155/4885AKR1C3 1219/4885AKR1C2 845/4885 |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, HDGF | KMT2A 4194/4885AKR1C3 1127/4885AKR1C2 726/4885 |
| US-20020115711-A1 | Dibenzo[c]chromen-6-one derivatives as anti-cancer agents | DDB1, EDF1, DBN1 | KMT2A 4072/4885AKR1C3 3143/4885AKR1C2 2886/4885 |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | MKI67, VEGFA, TYR | KMT2A 2995/4885AKR1C3 814/4885AKR1C2 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.